Life Sciences Cases 2026: An Installed Base and a Test

The instrument is a placement and the test is the business

Write the revenue line the way this sector actually earns.

Revenue equals the installed base of instruments, times tests per instrument per period, times price per test. Cost of goods is the consumable, per test. The instrument itself is capital deployed into a customer site, recovered through the consumable rather than sold.

Three things follow, and none of them appears in a standard unit economics tree.

The first is that the unit of account is the test rather than the instrument. A company with 1,200 analyzers and one with 1,200 analyzers running at half the throughput are different businesses, and only the test count tells them apart.

The second is that the price per test is set by somebody else. Medicare publishes a fee schedule, commercial payers negotiate against it, and the company's pricing power is mostly the mix between them.

The third is that nothing sells until a regulator says so. The FDA is explicit that "until the submitter receives an order declaring a device SE, the submitter may not proceed to market the device", and that the determination "is usually made within 90 days", checked 30 September 2026 at fda.gov. That is a dated gate to put in a launch plan rather than a vague risk.

For a top down sanity check on any volume you build, US health spending reached "$5.3 trillion or $15,474 per person" in 2024, checked 30 September 2026 at cms.gov. Those two figures imply a population of 342.5 million, which is the denominator for a per capita test rate.

Alder Diagnostics, a life sciences case priced per test

Alder sells a molecular respiratory panel. The chief executive wants to know whether to place 300 more analyzers next year. Here is the position, and note which lines are assumptions.

1. Installed base. 1,200 analyzers in hospital laboratories.
2. Throughput. 14 tests a day, 300 operating days a year.
3. Medicare price. $46.50 a test, an assumed rate rather than a figure we read in the fee schedule files.
4. Commercial price. $71.00 a test on average.
5. Payer mix. 38 percent Medicare, 62 percent commercial.
6. Consumable cost. $19.40 a test.
7. Analyzer cost. $28,000 to build, ship and install, placed at no charge.

Volume first, and keep the unit visible. Each analyzer runs 14 tests a day across 300 days, which is 4,200 tests a year. Then 1,200 analyzers at 4,200 tests is 5.04 million tests a year.

Price second. Blend the two payers rather than averaging them, because the mix is not fifty fifty. 38% on $46.50 is $17.67, and 62% on $71.00 is $44.02. The blended price is $61.69 a test.

Margin third. Take off the $19.40 consumable and the gross margin is $42.29 a test. Then 5.04 million tests at $42.29 is $213.1 million of annual gross margin.

Eight weeks of payback on a free analyzer

Now price the placement decision the chief executive asked about.

One analyzer returns 4,200 tests at $42.29, which is $177,618 of gross margin a year. It costs $28,000. So the payback is 28,000 divided by 177,618, which is 0.158 of a year, or about 58 days.

Say what that shows rather than restating it. A placement pays for itself inside two months of running at assumed throughput. Capital is therefore not what limits growth here, and 300 analyzers cost 300 at $28,000, which is $8.4 million against $213.1 million of existing gross margin. Placement capacity is the binding constraint, and money is not.

That reframes the whole case. The question stops being whether to fund 300 analyzers and starts being whether Alder can find 300 laboratories with 14 tests a day of genuine demand, install them, and train the staff. The answer lives in field force capacity and in hospital procurement cycles.

Test the assumption the payback rides on. At 7 tests a day instead of 14, an analyzer runs 2,100 tests and returns $88,809 a year, and the payback is 28,000 over 88,808, which is 0.315 of a year, or about 115 days. Still fast. The placement model survives a halving of throughput, which is genuinely unusual and worth stating as the strength of the business.

A life sciences fee schedule that may only fall fifteen percent a year

Here is the risk that decides Alder's five year plan, and it is written in a rule rather than guessed.

CMS pays "for most clinical diagnostic laboratory tests (CDLTs) based off the weighted median of private payor rates", updating "using private payor rates every 3 years" under the Protecting Access to Medicare Act. It adds that there is "no phase-in reduction in 2026" and that "beginning January 1, 2027 - 2029, payment may not be reduced by more than 15% percent per year compared to the payment amount established for a test the preceding year", checked 30 September 2026 at cms.gov.

Two things in that passage matter to the model. The Medicare price is derived from commercial prices, so it follows them down with a lag. And the fall is capped per year, which turns a cliff into a staircase.

Walk the staircase on Alder's $46.50. 15% on $46.50 is $6.98, so 2027 pays $39.53. Another 15 percent takes 2028 to $33.60. Another takes 2029 to $28.56.

Now do the arithmetic carefully, because the cap compounds rather than adding up. The factor is 0.85 cubed, which is 0.614, so the cumulative fall is 38.6 percent and never the 45 percent a subtraction suggests. The difference between 45 and 38.6 is worth $5.7 million of gross margin on this volume, so the shortcut and the correct figure disagree by a sum the client would notice.

Read the right column. The Medicare rate falls 38.6 percent and the gross margin falls 16.1 percent, because 62 percent of the volume is priced commercially and the consumable cost does not move. The blended figure for 2029 checks out: 38% on $28.56 is $10.85, plus the unchanged $44.02, which is $54.87.

Where a diagnostics answer goes wrong

Our own grader puts four weights on a piece of case arithmetic. They are our weights, read from the rubric code in this repository, and neither CMS nor the FDA endorses any scoring of case answers. The argument for each of the four is written out on how an answer is assessed.

Drilling the per test chain a life sciences case needs

Rework Alder one input at a time, and name the unit before each product.

Mix first, because it is the lever the company controls. Take Medicare from 38 to 30 percent of volume. The blended price becomes 0.30 times 46.50 plus 0.70 times 71.00, which is $13.95 plus $49.70, so $63.65. Gross margin per test becomes $44.25, and 5.04 million tests at $44.25 is $223.0 million. Eight points of mix is worth $9.9 million a year, which recovers about 29 percent of what three years of capped Medicare cuts take away.

Consumable cost second. Take it from $19.40 to $16.50. Gross margin per test becomes $45.19, and on 5.04 million tests that is $227.8 million, worth $14.7 million a year. Manufacturing has a bigger lever here than pricing does, and that is the sort of conclusion a client does not expect.

Then question the 300 operating days. A hospital laboratory running seven days a week has 365, and one running weekdays only has about 250. The gap between 250 and 365 is 46 percent of the volume in this model, which makes the operating calendar a bigger swing than every pricing scenario above.

Our breakeven calculator solves the placement threshold when a case asks how many analyzers cover a fixed cost, and the math drill times chains like the blended price and grades Units separately. Both are free and need no account.

For the payer side of the same system, counted per member per month, see healthcare cases. For net price after rebates and the patent cliff, see pharma cases. For sizing a market before pricing into it, see the market entry framework.